Molecular determinants of cetuximab efficacy

Journal of Clinical Oncology

Volumn 23, Issue 15, 2005, Pages 3536-3544

  Vallböhmer, Daniel ^a   Zhang, Wu ^a   Gordon, Michael ^a   Yang, Dong Yun ^a   Yun, Jim ^a   Press, Oliver A ^a   Rhodes, Katrin E ^a   Sherrod, Andy E ^a   Iqbal, Syma ^a   Danenberg, Kathleen D ^a   Groshen, Susan ^a   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CYCLIN D1; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 8; IRINOTECAN; OXALIPLATIN; VASCULOTROPIN; MEMBRANE PROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY; PROSTAGLANDIN SYNTHASE; PTGS2 PROTEIN, HUMAN; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HUMAN; LASER CAPTURE MICRODISSECTION; MALE; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; CANCER STAGING; COLORECTAL TUMOR; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PILOT STUDY; PROBABILITY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HUMANS; INTERLEUKIN-8; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; PROBABILITY; PROGNOSIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 20644447818     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.09.100     Document Type: Article

References (38)

1. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54:8-29, 2004
2. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
3. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
4. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
5. Herbst RS, Shin DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy. Cancer 94:1593-1611, 2002
6. Salomon DS, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995
7. Mayer A, Takimoto M, Fritz E, et al: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71:2454-2460, 1993
8. Hemming AW, Davis NL, Kluftinger A, et al: Prognostic markers of colorectal cancer: An evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol 51:147-152, 1992
9. El-Rayes BF, LoRusso PM: Targeting the epidermal growth factor receptor. Br J Cancer 91:418-424, 2004
10. Veronese ML, O'Dwyer PJ: Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer 40:1292-1301, 2004
11. Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 19:6550-6565, 2000
12. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201-1208, 2004
13. Lenz HJ, Mayer RJ, Gold PJ, et al: Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. J Clin Oncol 22:247s, 2004 (abstr 3510)
14. Tabernero M, Van Cutsem E, Sastre J, et al: An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR): Preliminary results. J Clin Oncol 22:248s, 2004 (abstr 3512)
15. Pai R, Soreghan B, Szabo IL, et al: Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8:289-293, 2002
16. Poch B, Gansauge F, Schwarz A, et al: Epidermal growth factor induces CCND1 in human pancreatic carcinoma: Evidence for a CCND1- dependent cell cycle progression. Pancreas 23: 280-287, 2001
17. Perrotte P, Matsumoto T, Inoue K, et al: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5:257-265, 1999
18. Maity A, Pore N, Lee J, et al: Epidermal growth factor receptor transcriptionally upregulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 60:5879-5886, 2000
19. Bonner RF, Emmert-Buck M, Cole K, et al: Laser capture microdissection: Molecular analysis of tissue. Science 278:1481-1483, 1997
20. Lord RV, Salonga D, Danenberg KD, et al: Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 4:135-142, 2000
21. Guba M, Seeliger H, Kleespies A, et al: Vascular endothelial growth factor in colorectal cancer. Int J Colorectal Dis 19:510-517, 2004
22. Parikh AA, Fan F, Liu WB, et al: Neuropilin-1 in human colon cancer: Expression, regulation, and role in induction of angiogenesis. Am J Pathol 164:2139-2151, 2004
23. Ciardiello F, Bianco R, Damiano V, et al: Antiangiogenic and antitumor activity of antiepidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6:3739-3747, 2000
24. Ravindranath N, Wion D, Brachet P, et al: Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 22:432-443, 2001
25. Goldstein NS, Armin M: Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system. Cancer 92:1331-1346, 2001
26. Khorana AA, Ryan CK, Cox C, et al: Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: A role for the host response in prognosis. Cancer 97:960-968, 2003
27. Resnick MB, Routhier J, Konkin T, et al: Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: A tissue microarray study. Clin Cancer Res 10:3069-3075, 2004
28. Sinicrope FA, Gill S: Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 23: 63-75, 2004
29. Kinoshita T, Takahashi Y, Sakashita T, et al: Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochim Biophys Acta 1438:120-130, 1999
30. Li A, Varney ML, Singh RK: Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin Cancer Res 7:3298-3304, 2001
31. Denkert C, Kobel M, Pest S, et al: Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 160:893-903, 2002
32. Gallo O, Masini E, Bianchi B, et al: Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol 33:708-714, 2002
33. Yuan A, Yang PC, Yu CJ, et al: Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med 162:1957-1963, 2000
34. Busam KJ, Capodieci P, Motzer R, et al: Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144: 1169-1176, 2001
35. Kulkarni S, Rader JS, Zhang F, et al: Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 7:429-434, 2001
36. Richardson CM, Sharma RA, Cox G, et al: Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: Potential targets for chemoprevention and systemic therapy. Lung Cancer 39:1-13, 2003
37. Lin E, Morris JS, Ayers GD: Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Huntingt) 16:31-37, 2002 (suppl 14)
38. Sonis ST, O'Donnell KE, Popat R, et al: The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol 40:170-176, 2004